期刊
SURGICAL CLINICS OF NORTH AMERICA
卷 93, 期 2, 页码 493-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.suc.2013.01.006
关键词
Neoadjuvant chemotherapy; Trastuzumab; Nodal disease; Breast cancer
类别
Randomized prospective trials have demonstrated that patients with early-stage breast cancer preferring breast conservation can benefit from neoadjuvant chemotherapy, achieving about a 25% complete and greater than 80% partial pathologic response. These responses do not translate into a survival advantage. For earlier stage patients, neoadjuvant chemotherapy's primary advantage is the ability to increase the use of breast conservation. Patients who opt for neoadjuvant chemotherapy should have a clinical and radiographic assessment of the axilla. The inability to predict the extent and pattern of response to chemotherapy requires that surgeons monitor patient response during neoadjuvant chemotherapy to provide optimal surgical planning.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据